Nat Rev Drug Discov

Abstract

Improving the effectiveness of preclinical predictions of human drug responses is critical to reducing costly failures in clinical trials. Recent advances in cell biology, microfabrication and microfluidics have enabled the development of microengineered models of the functional units of human organs - known as organs-on-chips - that could provide the basis for preclinical assays with greater predictive power. Here, we examine the new opportunities for the application of organ-on-chip technologies in a range of areas in preclinical drug discovery, such as target identification and validation, target-based screening, and phenotypic screening. We also discuss emerging drug discovery opportunities enabled by organs-on-chips, as well as important challenges in realizing the full potential of this technology.1DP2HL127720-01/DP/NCCDPHP CDC HHS/United StatesDP2 HL127720/HL/NHLBI NIH HHS/United StatesP30 ES013508/ES/NIEHS NIH HHS/United States2016-04-09T00:00:00Z25792263PMC482638